206 related articles for article (PubMed ID: 14743202)
1. Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers.
Ogasawara S; Maesawa C; Yamamoto M; Akiyama Y; Wada K; Fujisawa K; Higuchi T; Tomisawa Y; Sato N; Endo S; Saito K; Masuda T
Oncogene; 2004 Feb; 23(5):1117-24. PubMed ID: 14743202
[TBL] [Abstract][Full Text] [Related]
2. Silencing of the maspin gene by promoter hypermethylation in thyroid cancer.
Boltze C; Schneider-Stock R; Quednow C; Hinze R; Mawrin C; Hribaschek A; Roessner A; Hoang-Vu C
Int J Mol Med; 2003 Oct; 12(4):479-84. PubMed ID: 12964023
[TBL] [Abstract][Full Text] [Related]
3. Loss of maspin expression is associated with development and progression of gastric carcinoma with p53 abnormality.
Ito R; Nakayama H; Yoshida K; Oda N; Yasui W
Oncol Rep; 2004 Nov; 12(5):985-90. PubMed ID: 15492782
[TBL] [Abstract][Full Text] [Related]
4. Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells.
Akiyama Y; Maesawa C; Ogasawara S; Terashima M; Masuda T
Am J Pathol; 2003 Nov; 163(5):1911-9. PubMed ID: 14578190
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells.
Wada K; Maesawa C; Akasaka T; Masuda T
J Invest Dermatol; 2004 Mar; 122(3):805-11. PubMed ID: 15086568
[TBL] [Abstract][Full Text] [Related]
6. Effects of demethylating agent 5-aza-2(')-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines.
Murakami J; Asaumi J; Maki Y; Tsujigiwa H; Kuroda M; Nagai N; Yanagi Y; Inoue T; Kawasaki S; Tanaka N; Matsubara N; Kishi K
Oral Oncol; 2004 Jul; 40(6):597-603. PubMed ID: 15063388
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of maspin expression in human ovarian carcinoma cells.
Rose SL; Fitzgerald MP; White NO; Hitchler MJ; Futscher BW; De Geest K; Domann FE
Gynecol Oncol; 2006 Aug; 102(2):319-24. PubMed ID: 16457875
[TBL] [Abstract][Full Text] [Related]
8. [Role of the class II tumor suppressor gene maspin in thyroid carcinogenesis].
Boltze C; Hoang-Vu C; Schneider-Stock R; Lehnert H; Roessner A
Verh Dtsch Ges Pathol; 2004; 88():237-45. PubMed ID: 16892558
[TBL] [Abstract][Full Text] [Related]
9. Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer.
Kong WJ; Zhang S; Guo C; Zhang S; Wang Y; Zhang D
Laryngoscope; 2005 Aug; 115(8):1395-401. PubMed ID: 16094112
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
11. Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation.
Yatabe Y; Mitsudomi T; Takahashi T
Oncogene; 2004 May; 23(23):4041-9. PubMed ID: 15048080
[TBL] [Abstract][Full Text] [Related]
12. 5-Aza-2'-deoxycytidine enhances maspin expression and inhibits proliferation, migration, and invasion of the bladder cancer T24 cell line.
Zhang H; Qi F; Cao Y; Zu X; Chen M; Li Z; Qi L
Cancer Biother Radiopharm; 2013 May; 28(4):343-50. PubMed ID: 23570371
[TBL] [Abstract][Full Text] [Related]
13. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
14. Promoter methylation of cyclin D2 gene in gastric carcinoma.
Oshimo Y; Nakayama H; Ito R; Kitadai Y; Yoshida K; Chayama K; Yasui W
Int J Oncol; 2003 Dec; 23(6):1663-70. PubMed ID: 14612939
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of maspin gene expression in human breast cancers.
Domann FE; Rice JC; Hendrix MJ; Futscher BW
Int J Cancer; 2000 Mar; 85(6):805-10. PubMed ID: 10709100
[TBL] [Abstract][Full Text] [Related]
16. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
17. MnSOD up-regulates maspin tumor suppressor gene expression in human breast and prostate cancer cells.
Duan H; Zhang HJ; Yang JQ; Oberley LW; Futscher BW; Domann FE
Antioxid Redox Signal; 2003 Oct; 5(5):677-88. PubMed ID: 14580325
[TBL] [Abstract][Full Text] [Related]
18. RIZ1 is epigenetically inactivated by promoter hypermethylation in thyroid carcinoma.
Lal G; Padmanabha L; Smith BJ; Nicholson RM; Howe JR; O'Dorisio MS; Domann FE
Cancer; 2006 Dec; 107(12):2752-9. PubMed ID: 17103461
[TBL] [Abstract][Full Text] [Related]
19. Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer.
Bettstetter M; Woenckhaus M; Wild PJ; Rümmele P; Blaszyk H; Hartmann A; Hofstädter F; Dietmaier W
J Pathol; 2005 Apr; 205(5):606-14. PubMed ID: 15714592
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation of maspin expression in the human placenta.
Dokras A; Coffin J; Field L; Frakes A; Lee H; Madan A; Nelson T; Ryu GY; Yoon JG; Madan A
Mol Hum Reprod; 2006 Oct; 12(10):611-7. PubMed ID: 16936308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
